

PARABLE

PARABLE: Proton beAm theRApy in patients with Breast cancer: evaluating early and Late Effects

PATIENT INFORMATION SHEET

Version 1.2, 26th January 2023

Invitation to take part in a research study

- You are being invited to take part in a research study called PARABLE.
- Before you decide whether to participate, it is important for you to understand why the research is being done and what it will involve.
- In this information sheet you will be able to find details on why the study is being done, why you have been invited to take part and what will be involved if you decide to take part.
- Please take time to read this information sheet carefully and discuss it with friends, relatives and your GP if you wish.
- Please ask your study doctor or nurse if there is anything that is not clear or if you would like more information.
- Please take as much time as you need to decide whether or not you wish to take part in PARABLE.
- Your participation is entirely voluntary. If you decide not to take part this will not affect your standard of care or any future care you will get.
- If you decide to take part, you will be asked to sign the consent form at the end of this information sheet. You will be given a copy of this information sheet and a signed consent form to take home with you.
- Even after you have signed the consent form, you can change your mind at any time and withdraw from the study. You do not have to give a reason.

REC Ref: 21/WS/0171, IRAS Project ID: 302709; CCR number: CCR5523

Why is this study being conducted and what does it involve?

- PARABLE aims to compare Proton Beam Therapy (PBT), a type of radiotherapy that uses protons (high-energy charged particles) rather than x-rays to treat cancer, in breast cancer patients who have a slightly higher risk of developing side-effects from radiotherapy.
- PBT delivers a dose to a specific depth so may give better dose coverage where needed with less unwanted heart dose for patients at slightly higher risk of side-effects. We want to see if PBT reduces the predicted small risk of long-term serious heart problems whilst not increasing other more common shorter-term side-effects, such as skin changes.
- We are able to estimate your potential small risk of long-term heart problems later in life from radiotherapy (also known as your 'lifetime risk') using information from the radiotherapy planning scan that you have already had. We can estimate the average radiotherapy dose that your heart is likely to receive from the radiotherapy planning scan. This information, in addition to your age and other medical history is used to predict your potential small lifetime risk of heart problems.
- Patients with a '2% or more' potential lifetime risk of heart problems are the most likely to benefit from proton beam therapy (PBT). We think that you may have a '2% or more' small potential lifetime risk of heart problems from radiotherapy and therefore you are being invited to take part in this study.
- Approximately 192 people will take part in this study. Half of patients will receive PBT at one of two NHS proton centres in Manchester or London. If you do not live near a PBT centre accommodation is available whilst you receive treatment, however you may need to pay for the cost of travelling from your home for treatment planning and delivery. Further details are provided in this information sheet.
- The other half of patients will receive tailored radiotherapy 'tailored RT' at their local radiotherapy centre. **Tailored RT given to patients within PARABLE is the most targeted and modern radiotherapy (using x-rays) available worldwide.** Both types of radiotherapy are given once a day (weekdays), over a 3 week period.
- If you take part in this study you will be followed for up to 5 years after treatment and will be asked to complete a number of questionnaires throughout this period so we can better understand the effects of PBT both in the short term and over a longer period of time.
- If you take part in this study you will be asked if you would like to donate some blood samples and/or tumour samples for use in research. However, you can still take part in the study even if you do not wish to do this.
- Information about your health will be provided to the study research team by your local hospital team during and after treatment in order to undertake this study. National records, which are kept on everyone's health status, will also be used by the study research team to find out how you are getting on. All information about you which is collected during the study will be kept strictly confidential and will be stored securely.

Contents

PART 1.....	4
1 Why are we doing this study?.....	4
2 Why am I being invited to take part?.....	4
3 What will happen to me if I take part?.....	5
4 Do I have to take part?.....	5
5 How will you decide which treatment to give me?.....	5
6 What happens during my treatment?.....	6
7 What other study specific assessments will be performed?.....	8
8 Will I be asked to do anything else?.....	9
9 What are the possible benefits of taking part in this study?.....	9
10 What are the possible disadvantages and risks of taking part in this study?.....	9
11 What if the radiotherapy planning process shows I am not suitable for this study?.....	10
12 What happens if I don't want to carry on with the study?.....	10
PART 2.....	11
1 Support for patients participating in PARABLE.....	11
2 More information about Biological Sample and Imaging Donation.....	12
3 Who is organising and funding the research?.....	13
4 Confidentiality.....	13
5 Further Information.....	15
4 Useful contact information.....	17

PART 1

1 Why are we doing this study?

Around 33,000 breast cancer patients/year need radiotherapy as part of their treatment. For around 500/year) radiotherapy may be more difficult due to the need to treat lymph nodes near the breast-bone. A person's body shape can also make treatment difficult. This can result in less radiotherapy dose where needed and/or unwanted dose to healthy tissue such as heart (increasing the small risk of serious heart problems many years later).

Proton Beam Therapy (PBT) is a type of radiation therapy. It uses protons (high-energy charged particles) rather than x-rays to treat cancer. PBT can be more targeted than x-rays potentially reducing risks of side-effects in normal tissues such as the heart. We want to compare PBT with tailored radiotherapy 'tailored RT' (tailored RT delivered within PARABLE is the most targeted and modern radiotherapy using x-rays available worldwide) in breast cancer patients who may be at higher risk of side-effects from radiotherapy.

PBT delivers dose to a defined depth giving better dose coverage where needed with less dose to the heart. Although increased skin and rib side-effects around 2 years after treatment have been reported with older PBT techniques (delivered over 5 weeks), newer PBT techniques do not appear to cause these issues, although numbers are small with no direct comparison to radiotherapy. In the UK, radiotherapy is delivered over 3 weeks as clinical trials have shown this to be as good as 5 weeks with fewer side-effects.

The NHS has 2 PBT centres in Manchester (opened 2018) and London (opening 2021). **We want to compare PBT with tailored RT to see if PBT reduces the predicted very small risk of long-term serious heart problems whilst not increasing other more common shorter-term side-effects such as skin changes.**

2 Why am I being invited to take part?

We are able to predict your potential small risk of developing long-term heart problems later in life from radiotherapy (also known as your 'lifetime risk') using information from the radiotherapy planning scan that you have already had. We can estimate the average radiotherapy dose that your heart is likely to receive from the radiotherapy planning scan. This information, in addition to your age and other medical history is used to predict your potential small lifetime risk of heart problems.

Patients with a '2% or more' potential lifetime risk of heart problems are the most likely to benefit from proton beam therapy (PBT). We think that you may have a '2% or more' small potential lifetime risk of heart problems from radiotherapy and therefore you are being invited to take part in this study. If you join the study, you will be one of 192 people from around the UK taking part.

3 What will happen to me if I take part?

If you decide to take part then you will be asked to sign a consent form. Following this, you will be asked to provide details of your medical history and you will be asked to complete a number of questionnaires. You will then be randomised to receive either tailored RT or PBT (the randomisation process is described below).

During your treatment you will be assessed regularly by the research team and you will be asked to complete a number of questionnaires regarding your side-effects. After completion of your treatment you will continue to be followed up by your research team for at least 5 years. You will also be asked to complete a number of questionnaires during this time.


4 Do I have to take part?

No, it is up to you to decide whether or not to take part in this study. Your participation is entirely voluntary and you will be given sufficient time to decide if you wish to participate. The standard of care you receive will not be affected by your decision to take part, or not take part, in PARABLE. If you do agree to participate in the study you are free to decide to end your participation at any time. You do not have to give a reason.

5 How will you decide which treatment to give me?

If you decide to take part in PARABLE you will receive either tailored RT (which is the most targeted and modern radiotherapy available worldwide) or PBT. The choice as to which type of radiotherapy you receive is made at random, by a computer, at the time you enter the study. This process is called 'randomisation'. This is the best way to make sure that the patients in each group are as similar as possible. If one group fares differently to another group, it is more likely to be because of the treatment, rather than because the patients in one group are somehow different to those in the other group.

Half of participants in PARABLE will receive tailored RT, the other half will receive PBT. Whichever group you are randomised to, everybody who takes part in the trial will receive the best possible care and regular monitoring by their clinical team.



Tailored RT

If you receive tailored RT you will receive 15 treatments of radiotherapy to the breast/chest wall and lymph nodes, one treatment a day (weekdays) over 3 weeks. In most cases, it will be possible to use the radiotherapy planning scan that you have already had to plan this treatment. All treatment and follow up will take place at your local radiotherapy centre.

Proton Beam Therapy (PBT)

If you receive PBT you will receive 15 treatments of radiotherapy to the breast/chest wall and lymph nodes, one treatment a day (weekdays), over 3 weeks. Treatment will take place at either The Christie NHS Foundation Trust in Manchester or University College Hospital in London (UCLH). **You will also require an additional CT planning scan at your NHS proton centre if you are in the proton beam group.** Following completion of treatment, you will return to your local hospital for the remainder of the study follow up.

Part 2 of this information sheet provides more information about the support, accommodation and financial assistance provided to patients receiving PBT.

6 What happens during my treatment?

Tailored RT and PBT involves treatments of 15 sessions once daily (weekdays) over 3 weeks.

Each treatment session will take approximately 20-45 minutes, as the radiographer needs to position you on the radiotherapy couch and ensure that you are comfortable before treatment begins. The total amount of time needed will depend on which treatment you receive. On average, the whole process for each treatment will take approximately 30 minutes for tailored RT and 45 minutes for PBT. You will not feel anything, as it is similar to having an X-ray scan.


How many times will I need to visit the hospital during and after my treatment?

You will be assessed regularly by your hospital doctor and/or nurse/radiographer during and after treatment. This is so they can assess the side-effects of your treatment.

- During radiotherapy treatment (tailored RT or PBT) you will be assessed every week.
- When the radiotherapy treatment is completed you will receive all further follow-up at your local hospital/radiotherapy centre.
- You will be assessed by your research team for early side-effects at 2 weeks after treatment (i.e. 5 weeks from the date you started treatment). If you have ongoing symptoms after 2 weeks you will continue to be assessed weekly either at your local hospital/radiotherapy centre until you have one or no symptoms. These assessments may be conducted in person at your local hospital or radiotherapy centre or remotely via telephone or video consultation. This will depend on your local hospital/radiotherapy centre's standard arrangements for these types of assessment.

- You will be assessed for possible late side-effects at your local hospital 3 months after completion of radiotherapy and then at 6, 12, 24 months after treatment. After this time we would like to assess you every year for the next 3 years. Your local hospital will have arrangements in place for these assessments to occur either in person at clinic or remotely via telephone or video consultation.
- You will have a CT scan of the chest at 24 months to investigate possible effects of treatment (PBT and tailored RT) on the lungs and ribs. You will also have a blood test at 24 months to check your thyroid function.

Summary of assessments



7 What other study specific assessments will be performed?


Before you start treatment we will assess the following:

- Medical history
- Weight and height
- Baseline questionnaires
- Optional blood sample

Completion of questionnaire booklets

All patients who take part in the study need to complete questionnaires, so we can understand your possible side-effects and how these may affect your quality of life. The information will also be helpful to guide your care, as we follow you up after treatment.

A member of your research team will explain the questionnaire and answer any questions that you have. Some of the questions may seem to be a bit repetitive but these are standard questionnaires and we would ask you to please bear with us and answer them as best you can.



You will be given your first questionnaires in clinic. These will be completed before treatment and before we know whether you will have tailored RT or PBT (to understand your symptoms at the outset).

You will also be asked to complete questionnaires weekly during treatment (Weeks 1-3) and then weekly for a further 9 weeks (Weeks 4-12) to assess early side-effects you may be experiencing. We will try to keep most of these as short as possible. Your first questionnaire (before treatment) will take the longest to complete (20-30 minutes). After this we will only ask you to give more detailed responses if you are experiencing any side-effects. These will take between 10-15 minutes.

You will then be asked to complete questionnaires at 6, 12, 24 and 60 months after treatment to assess your late side-effects and quality of life. Each questionnaire booklet should take about 30-40 minutes to complete.

From 6 months onwards these will be sent directly to you at your home address by researchers at the Institute of Cancer Research Clinical Trials and Statistics Unit (ICR-CTSU) where the study is being coordinated. We need to collect details of your home address in order to do this. We will check with your GP and/or hospital doctor before we contact you to make sure that you are well. The information you provide will be treated in the strictest confidence.

PATIENT REPORTED LATE SIDE EFFECTS, Quality of Life (QoL) and Health Resource Usage

6 MONTHS → 12 MONTHS → 24 MONTHS → 60 MONTHS

The PARABLE team at ICR-CTSU will send questionnaires directly to you at these timepoints. These will collect information on any late side effects, your quality of life and any relevant healthcare resource usage

We would also like to collect information about how you use healthcare resources, such as hospital or GP visits and any healthcare related activities, whilst you are taking part in the trial. We will ask about this in the questionnaires provided but would also need to use your NHS number to link with national databases.

8 Will I be asked to do anything else?

As part of PARABLE we are asking patients if they would like to consent to donate biological samples, including blood and tumour tissue. These will be for future research to contribute to the understanding of breast cancer and response to treatment for future patients. Further information about the type of samples and how these will be stored and analysed in the future can be found in Part 2 of this information sheet.

This is entirely voluntary and you do not have to agree to provide these samples to take part in PARABLE. If you do wish to donate biological samples we will ask you to provide consent for this when you consent to take part in the trial.

9 What are the possible benefits of taking part in this study?

There is no guarantee that you as an individual will benefit directly from taking part in this study although participating in PARABLE means that you will be treated with either tailored RT, which is the most targeted and modern radiotherapy using x-rays available worldwide, or PBT. We hope the information we gain from the study will benefit people who develop breast cancer in the future. You will have helped by taking part.

10 What are the possible disadvantages and risks of taking part in this study?

If you are randomised to receive PBT your treatment will take place at either The Christie NHS Foundation Trust in Manchester or University College Hospital in London rather than your local radiotherapy centre. Which PBT centre you attend will depend on your location and also which centre has availability for treatment. In some circumstances, this may not be your closest PBT centre. You will need to attend for a pre-treatment visit for radiotherapy planning and treatment at the NHS proton centre. You will also require an additional CT planning scan at the NHS proton centre.

If you live outside Manchester or London and receive PBT as part of the study, it may mean being away from home for treatment if it is too far to travel daily. A family member, friend or carer can come with you, and you will be supported by a team of doctors, nurses and other health professionals at the NHS proton centre. If you do not live near the NHS proton centre, arrangements will be in place to support accommodation and travel requirements. Further details are provided in part 2.

Pregnancy during treatment

Radiotherapy can be harmful to a developing baby. You should not become pregnant before or during treatment. Appropriate contraception should be used. Your clinical team can advise you on appropriate methods of contraception. If you think you may be pregnant, you must tell the nurses, radiographers or your hospital doctor before you have any treatment.

Are there any radiation risks associated with this study?

Radiotherapy causes a number of short-term side effects which your doctor will discuss with you. These effects will be similar to those you would experience if you had standard radiotherapy outside this study. The risk of longer-term side effects on heart and lungs from both tailored x-ray therapy and proton beam therapy is low, but you have been invited to take part in this study because we think proton beam therapy could reduce these risks further. Radiotherapy and CT scans use radiation to inform images and provide treatment. This radiation may cause cancers to develop many years or decades after the exposure. These 2nd cancer risks are very low and likely to be similar for both tailored x-ray therapy and proton beam therapy. We will be monitoring this as part of the longer term follow-up in this study. If you are randomised to receive PBT you will need a second radiotherapy planning scan at your proton beam centre. If you are randomised to having tailored RT you *may* need a second radiotherapy planning scan at your local centre. The second radiotherapy planning scans are not normally part of your routine care. All patients in the study (regardless of whether you have tailored RT or PBT) will have a CT scan of the chest at 2 years. These CT scans would not normally be part of your routine care. You may also receive additional imaging during your treatment, compared to your routine care in order to further improve accuracy of your treatment. The radiation dose from all the additional scans will be small compared to the dose from your radiotherapy and will not significantly change the risk of developing cancer at a much later date.

11 What if the radiotherapy planning process shows I am not suitable for this study?

If for some reason the tests show you should not take part in the study your hospital doctor will discuss alternatives with you.

12 What happens if I don't want to carry on with the study?

You are free to withdraw from the study at any time. You do not have to give a reason and your future treatment will not be affected. Your doctor will discuss your treatment with you and will offer you the most suitable treatment available.

However, if you were to withdraw, we would like your permission please to keep the information and samples we have already collected from you and to continue to collect information on your progress that is routinely recorded in your medical records.

This completes PART 1 of the Information Sheet

If the information given in Part 1 of this information sheet has interested you and you are considering participation in the PARABLE study, please read the additional information in Part 2 before making a decision.

PART 2

1 Support for patients participating in PARABLE

Patients receiving Proton Beam Therapy

If you are allocated to proton beam therapy you will need to visit one of the two national NHS proton centres for treatment planning and the treatment itself. The proton centres are located at the Christie NHS Foundation Trust in Manchester and the University College Hospital London. Following your confirmation that you wish to take part in the study you will be contacted by a key worker (a named specialist nurse or radiographer from one of the proton centres), who will provide assistance and support throughout your treatment. If the proton centre is not part of your local hospital trust where you would receive radiotherapy as standard of care you plus one family member, friend or carer may be provided with accommodation near to the proton centre. Your key worker at the proton centre will call you to discuss travel and accommodation during treatment and to answer any questions you have before you arrive at the hospital. Please read all information you have received from your local hospital before this phone call, so that they can best manage your questions.

Accommodation during Proton Beam Therapy

If the NHS proton centre is not part of the hospital trust in which you would receive radiotherapy as standard of care, accommodation arrangements will be made by the key worker from the proton centre. This would be for you plus one family member, friend or carer for your planning visit and for the whole of your 3 week treatment. The types of accommodation available will vary to accommodate your specific needs. You do not have to stay in the provided accommodation if you live close to the NHS proton centre and/or would prefer to return home every day following your treatment.

Only accommodation approved by the NHS proton centre will be funded by the NHS. Further details about the accommodation provided will be provided by your local hospital.

Is there any financial support available?

Within the PARABLE trial there is no funding available to support travel from your home to the provided accommodation near to the proton centre. You would be responsible for covering the costs of your travel during screening and treatment. You may be eligible for financial support from your local hospital trust to cover these travel costs, but this would be dependent on local policy and you would need to discuss this with your local research team in the first instance.

Patients receiving Tailored RT

There is no funding available to support travel arrangements for patients allocated to receive tailored RT within the PARABLE trial. You would be responsible for covering the costs of your travel during screening and treatment, as with your usual standard care arrangements. You may be eligible for financial support from your local hospital trust, but this would be dependent on local policy and should be discussed with your local research team in the first instance.

2 More information about Biological Sample and Imaging Donation

What samples will I be asked to donate?

Blood Samples

We would like to collect blood samples from patients who join PARABLE. These will be stored for future research into breast cancer. This is optional and you do not have to donate blood samples to participate in the study.

If you provide your consent, one optional blood sample will be taken at baseline, once you have joined the study and before you have started your treatment.

Tissue Samples

When you had a diagnostic biopsy and when you had surgery for your breast cancer the tumour tissue that was removed was stored in your hospital's pathology laboratory. We would like to ask you to consent to donating some of this stored tissue for possible future research into breast cancer. This is optional and you do not have to donate this tissue to participate in the study.

Sometimes the breast cancer can return in the same breast or another cancer can develop in your opposite breast. Both of these are situations are unlikely to happen. If, however, you did develop breast cancer again we would also like to ask for your permission to collect a small part of tumour tissue taken from any routine biopsies or surgeries performed as part of your standard care.

This will give valuable information from tumour samples about breast cancer, radiotherapy treatment and why some cancers return and this may help further improve breast cancer treatment in the future.

If you develop another breast cancer then it is usual to have an imaging scan of the body as part of standard care. We will also ask you to consent to use of this imaging scan too as it gives important information about the position of the breast cancer.

What will happen to samples I donate?

Your samples will be sent to a specialist research laboratory and will be identified by your Trial ID, initials and date of birth only. Once at the research laboratory, they will be given a unique identification number and will be stored securely and in strict accordance with national guidelines.

The samples you donate may be used in the future for analysis that could include genetic analysis. Cancer can be caused by changes in our genes that occur after we are born. These changes would not be passed on in families. We can test for this type of change using the genetic material from cancer cells. This type of testing may be done on your samples if you agree to allow your samples to be used for future research.

We would also like to be able to make your samples and any information necessary for their analysis, including imaging scans performed if the cancer was to come back as part of standard care, available to other researchers for future medical research. This may involve researchers and organisations outside of the UK and European Economic Area (EEA). This could also include the genetic testing described above. It is possible that the future research will be carried out internationally.

Any future research using your tissue must be approved by an independent Ethics Committee before it is allowed to go ahead. Any tissues samples and information relating to them transferred to third parties will not contain your personal information, so researchers will not be able to identify you from the information provided.

It will not be possible to release the results of these future tests to you or your research doctor and they will not form part of your medical records.

3 Who is organising and funding the research?

PARABLE is being carried out by a network of doctors across the UK. The study is sponsored and coordinated by The Institute of Cancer Research (ICR). The research is approved and funded through the National Institute for Health Research – Efficacy and Mechanism Evaluation (EME) Programme. Your study doctor will not receive any payments for including you in this research study.

4 Confidentiality

How will the information about you be used?

The Institute of Cancer Research is the sponsor and will act as the data controller for this study based in the United Kingdom. This means that the ICR are responsible for looking after your information and using it properly when you have agreed to take part.

The ICR's lawful basis for processing your information is for the performance of a task carried out in the public interest and it is necessary to process sensitive health and genetic information for the purposes of scientific research with appropriate safeguards in place. The procedures for handling, processing, storage and destruction of your data will be compliant with the Data Protection Act 2018 and in accordance with the UK Policy Framework for Health and Social Care Research.

[insert appropriate name for NHS site] will collect information and samples from you and your medical records for this research study in accordance with our instructions.

This information will include your initials, full name, hospital number, date of birth, postcode and NHS number (or Community Health Index (CHI) and/or hospital number in Scotland). This information will be entered onto the ICR's clinical trial database, managed and maintained by us. Your information will be used to conduct the research and to check your records to make sure that the research is being done properly. At any time for purposes associated with our research, authorised people may look at your information, this includes people within the **[insert appropriate name for NHS site]**, and the ICR as well as regulatory authorities, Collaborators or other third parties approved by ICR which may have offices outside of the UK or Europe.

People who do not need to know who you are will not be able to see your name or contact details. Your data will have a Study number instead. We will keep all information about you confidential, safe and secure.

The information collected will be kept by the ICR for at least 5 years and by the **[insert appropriate name for NHS site]** for at least 5 years after the study has closed.

What are my choices about how my information is used?

You can stop taking part in the study at any time, without giving a reason, but we will keep information about you that we already have. We need to manage our records in specific ways for the research to be reliable and accurate. This means that your rights to access, change or move your information is limited. To safeguard your rights, we will use the minimum personally-identifiable information possible.

From time to time, we would like to know how you are getting on. Ideally, we would like to do this for life using national records which are kept on everyone's health status. One of these is held at the General Register Office (GRO). We will need to give them enough information to identify you. This usually includes your name, date of birth, postcode and NHS number (or Community Health Index (CHI) and/or hospital number in Scotland). Any details we receive from any source are confidential and will only be used for the purposes of the study. Please initial the consent form to show that we have your permission to do this.

For the purposes of our research, de-identified information about you including your samples may be transferred to researchers within or outside the UK and European Economic Area with appropriate safeguards, now or in the future. Some countries outside the UK and Europe may not have laws which protect your privacy to the same extent as the Data Protection Act in the UK or European Law. Your information could be used for research in any aspect of health or care, and could be combined with information about you from other sources held by researchers, the NHS or government. We will take all reasonable steps to protect your privacy. Where there is a risk that you can be identified your data will only be used in research that has been independently reviewed by an ethics committee.

Where can I find out more about how my information is used?

You can find out more about how we use your information or your rights:

- at <https://www.icr.ac.uk/legal/privacy>
- by sending an email to ICR's Data Protection Officer at dataprotectionofficer@icr.ac.uk
- at www.icr.ac.uk/our-research/centres-and-collaborations/centres-at-the-icr/clinical-trials-and-statistics-unit/transparency
- at www.hra.nhs.uk/information-about-patients

Involvement of your General Practitioner/family doctor

Your GP will be informed about your participation in PARABLE. This is to make sure that your GP knows you are taking part in the trial in case of any side-effects and/or drug interactions.

5 Further Information

What if something goes wrong?

Every care will be taken during the course of this clinical trial to ensure you receive appropriate care and treatment. If you are not happy with the general care and treatment you receive, please speak first to your doctor, who will try to resolve the problem. If you are still unhappy and wish to complain formally about the care and treatment received during the trial, you may do so under the standard NHS complaints procedure, which is available to you at your doctor's hospital.

[Sites in England] Concerns can also be raised by talking to your local Patient Advice and Liaison Service (PALS). You can contact the PALS team at **[insert Trust name]** on **[insert relevant contact details]**.

[Sites in Scotland] Concerns can also be raised by talking to the Patient Advice and Support Service (PASS). You can contact PASS via the National Citizens Advice Bureau on 0808800 9060 or through your local Citizens Advice Bureau (www.cas.org.uk/patientadvice).

[Sites in Wales] Concerns can also be raised by talking to the Patient Support and Advisory Service (PSAS). You can contact PSAS on 0300 0200 159 or emailing hdhb.patientsupportservices@wales.nhs.uk.

[Delete above sections as appropriate for location of trial site.]

You will be closely monitored both during and after treatment and any side-effects will be treated as appropriate. If you suffer any side-effects or injury, please notify your doctor immediately so you can obtain appropriate medical attention.

In the unlikely event that you are injured by taking part, compensation may be available.

If you are harmed due to the negligence of someone treating you, then you may have grounds for legal action but you might have to pay for it. NHS Trusts are responsible for clinical negligence and other negligent harm to individuals that are under their care and covered under the NHS Indemnity Scheme.

If you suffer adverse side-effects of the trial treatment or harm caused by procedures you have undergone specifically for the trial you may be able to claim compensation from The Institute of Cancer Research as sponsor of the PARABLE trial. In deciding the level of compensation to be awarded, consideration will be given to the likelihood of side-effects and any warnings that were given.

What if relevant new information becomes available?

Sometimes during the course of a study, new information becomes available about the treatment that is being studied. If this happens, your study doctor will tell you about it and discuss whether you want to, or should, continue in the study. If you decide not to carry on, your doctor will make arrangements for your continued care. If you decide to continue in the study you may be provided with an updated information sheet and be asked to sign an updated consent form.

If new information means it would be in your best interests to withdraw you from treatment in the trial, your doctor will explain the reasons for this and arrange for your continued care.

If the trial is stopped for any other reason, you will be told why and your doctor will arrange for your continued care.

What happens if I don't want to carry on with the trial?

You are free to withdraw from, or reduce your level of participation within, PARABLE at any time. You do not have to give a reason and your future treatment will not be affected by your decision. Your medical team will discuss your treatment options with you and will offer the most suitable treatment available.

If you were to reduce your participation, for example by stopping trial specific hospital visits, we would like to continue to collect information on your progress that is routinely recorded in your medical records. This is so that the overall quality of the study is not impaired and enough information is collected to answer the main aim of the trial.

If you decide you want to stop participation and do not want any more information to be sent to the research centre, trial data collected before your decision will still be processed along with other data collected as part of the clinical trial, however no new data will be added to the trial database and you may request that all retained identifiable samples are destroyed to prevent future analysis.

What will happen to the results of the study?

Independent experts will review the progress of the research and the results will be published in a medical or scientific journal as soon as there is enough information to be sure the results are reliable. You will not be identified in any report or publication. The results will help to decide how to treat breast cancer in the future.

Who has reviewed the trial?

All research in the NHS is reviewed at by an independent group of people, called a Research Ethics Committee, to protect participants' interests. This trial has been reviewed and given a favourable opinion by the West of Scotland Research Ethics Service. Their approval means they are satisfied that your rights

will be respected, that any risks have been reduced to a minimum and balanced against possible benefits, and that you have been given the right information to decide whether to take part. The trial has also been reviewed and approved by the Health Research Authority (HRA) and by the Committee for Clinical Research (CCR).

What happens now?

Your medical team will be happy to answer any questions. Once you have decided please let your medical team know. If you choose to join the PARABLE trial you will be asked to sign the consent form and will be given a copy to keep together with this information sheet.

4 Useful contact information

Who can I contact for further information?

You have the right to ask questions about this study at any time and are encouraged to do so. You can call your medical team if you feel that you are developing any side effects or if you have any questions about this study or your participation in this study.

Your hospital study doctor is: xxx

Your hospital study nurse is: xxxx

Contact phone numbers: xxxx

Out of hours number: xxxx

Macmillan Cancer Support is a registered charity providing information, emotional support and publications about all aspects of cancer for cancer patients and their families. You can contact one of their Cancer Information Nurse Specialists on the Macmillan Support Line; Freephone 0808 808 00 00, Monday to Friday, 9.00am to 8.00pm.

In addition to their nurses, the Macmillan Support Line also has other specialist teams that can provide advice and information relating to welfare benefits, financial issues and everyday practical concerns.

You can learn more about clinical trials on the Cancer Research UK patient website (www.cancerhelp.org.uk).

Thank you for your interest in our research